Introduction: The world's largest thunderstorm asthma (TA) event occurred on 21 November 2016 in Melbourne, Australia. A comprehensive review of evidence for contributing factors, gaps in knowledge and implications for public health was undertaken to better understand causation of this phenomenon.
Methods: Commissioned as a rapid review for The Victorian Department of Health and Human Services, a systematic search of medical and scientific literature with the terms 'thunderstorm' and 'asthma' was undertaken. Factors associated with TA were extracted and synthesised from 60 primary research articles identified from medical and scientific databases with search terms.
Results: TA events have been reported on 22 occasions including ten in Australia, although smaller spikes in springtime or thunderstormassociated asthma are more common. Exposure to high concentrations of bioaerosols, commonly grass pollen or fungal spores, with intense wind gust fronts (Australia) or lightning (UK) are particular features of TA. Sensitisation to triggering outdoor aeroallergens is prevalent but no single aeroallergen is ubiquitous. Consistently, close to 40% of affected patients had no previous asthma diagnosis whilst hay fever occurred at high frequency patients appeared not to be using appropriate medication beforehand. In the 2016 event, emergency services received 2666 calls with 962 for breathing difficulty; over 3365 patients with respiratory symptoms and 1428 with nil diagnosis presented to emergency departments; 35 patients were admitted to intensive care; and nine deaths were reported to the coroner in the 30 h following the arrival of the thunderstorm.
Conclusion: Local combinations of three types of interacting factors; aeroallergen exposure, meteorological conditions and individual susceptibility, appear to be necessary and synergistic component causes of TA. In Australia, aerobiological exposure to grass pollen and allergic sensitisation to ryegrass pollen, appear to be necessary but the role of age, sex, ethnicity, comorbidities of affected patients and air pollution are not clear. Due to the complexity and severity, understanding, predicting and preventing TA in Australia and elsewhere is an urgent public health priority. Background: Dupilumab, a fully human anti-interleukin (IL)-4R alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of type 2-mediated inflammation. In a pivotal phase 2b asthma study (NCT01854047), dupilumab 200/300 mg every 2 weeks (q2w) or every 4 weeks as add-on therapy to medium-to-high-dose inhaled corticosteroids plus a long-acting beta 2 -agonist (ICS+LABA) improved forced expiratory volume in 1 s (FEV 1 ), reduced severe asthma exacerbations, improved quality-of-life measures, and was generally well tolerated. This post hoc analysis evaluates the efficacy of dupilumab on FEV 1 , severe exacerbations, and asthma control in patients with comorbid chronic rhinosinusitis with/without nasal polyps (CRSwNP/CRSsNP), conditions that often coexist with asthma.
P58 DUPILUMAB EFFICACY AND EFFECT ON ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED PERSISTENT ASTHMA AND COMORBID CHRONIC RHINOSINUSITIS WITH OR WITHOUT NASAL POLYPS

Methods:
Changes from baseline to Weeks 12 and 24 in FEV 1 (L), annualised severe exacerbation rates in the 24-week treatment period, and change from baseline to Week 24 in the 5-item Asthma Control Questionnaire (ACQ-5) are reported for 93 (20.0%) asthma patients with a physician-based diagnosis of comorbid CRSwNP/CRSsNP from the intent-to-treat populations receiving placebo or dupilumab q2w, doses assessed in a phase 3 study (NCT02414854). Results: Of 5222 patients (mean age 46, SD 18), 3333 (63.8%) were sensitised to at least one grass pollen. Of these, 97.4% (n = 3246) were sensitised to at least one temperate and 87.3% (n = 2911) were sensitised to at least one subtropical grass pollen. 86.1% (n = 2870) were sensitised to both temperate and subtropical grasses. 12.7% (n = 422) and 1.2% (n = 41) were sensitised only to temperate or subtropical grasses respectively. Of those who were sensitised to a subtropical grass and tested for the other two subtropical pollens (n = 2856), 80.1% were sensitised to all. For those sensitised to a temperate grass and also tested to the six other temperate pollens, 95.8% were sensitised to rye grass, while 99.4% were sensitised to rye, timothy, brome and/or sweet vernal grass. No significant difference was seen between the proportion of grass-sensitised patients living in urban or rural areas sensitised to temperate grasses (98.0% and 95.3% respectively) or subtropical grasses (87.0% and 88.4% respectively) (P = 0.49).
Discussion/conclusion: In South Australia, co-sensitisation to temperate and subtropical grasses is common. This should be taken into account when prescribing immunotherapy, in particular sublingual extracts, which are limited to temperate grasses. Unique sensitisation to only one or two subtropical species is not uncommon. While sensitisation to rye grass is found in most temperate grass-sensitised patients, polysensitisation is common and a significant minority are not sensitised to rye grass; testing a minimum of 3-4 temperate grasses identifies 99.4% of temperate grass sensitised individuals. 
